1) Due to the availability of drugs, patient economic conditions, and medical insurance coverage, breast cancer patients in our center have only gradually begun to use anti-HER-2 drugs in recent years, especially dual-anti-HER-2 therapy. The gene discussed is ERBB2; the disease is breast carcinoma.